CJC-1295 + Ipamorelin Blend

The CJC-1295 Ipamorelin Blend is a pre-formulated research peptide that combines two distinct growth hormone-releasing compounds in a fixed 1:1 mass ratio. Each 10mg vial contains 5mg of CJC-1295 without DAC (also known as Mod GRF 1-29) and 5mg of Ipamorelin, co-lyophilized (also referred to as lyophilized) as a single powder cake for reconstitution with bacteriostatic water.

CJC-1295 no DAC is a 29-amino-acid tetrasubstituted analog (also referred to as an analog) of growth hormone-releasing hormone (GHRH). Four amino acid substitutions at positions 2, 8, 15, and 27 protect it from rapid enzymatic breakdown by DPP-IV, giving it a functional half-life of approximately 30 minutes compared to under 10 minutes for unmodified GHRH fragments like sermorelin. ⁽¹⁾ It acts at the GHRH receptor on pituitary somatotrophs to stimulate growth hormone (GH) synthesis and release. For a full breakdown of CJC-1295’s structure, DPP-IV resistance mechanism, and DAC vs no-DAC comparison, see the CJC-1295 no DAC (Mod GRF 1-29).

Ipamorelin is a pentapeptide growth hormone secretagogue that acts through the ghrelin receptor (GHS-R1a), a completely separate receptor system from the GHRH receptor. Unlike older ghrelin-receptor agonists such as GHRP-6 and GHRP-2, Ipamorelin stimulates GH release without producing significant elevations in cortisol, prolactin, or ACTH, even at doses more than 200-fold above its GH-releasing ED50. ⁽²⁾ This selectivity profile makes it the preferred GHRP-class compound for research protocols where clean GH data, free of confounding hormonal changes, is required. For full coverage of the individual mechanism, see the Ipamorelin.

The rationale for blending these two peptides is pharmacological: GHRH-receptor agonists and ghrelin-receptor agonists activate two independent intracellular pathways that converge on GH release. When both pathways fire simultaneously, the resulting GH pulse is synergistic rather than merely additive. ⁽³⁾ The blend format delivers this dual-receptor stimulation from a single vial at a verified ratio, removing the variability introduced by manual combination of separately sourced compounds.

The synergistic interaction between GHRH-receptor agonists and ghrelin-receptor agonists is one of the most consistently replicated findings in growth hormone physiology. Bowers ⁽¹⁹⁹⁹⁾ demonstrated that simultaneous stimulation of both receptor pathways produces a GH response significantly greater than the sum of the responses to either stimulus applied alone. ⁽³⁾ This is not a theoretical extrapolation; it is a directly measured pharmacodynamic outcome in both animal models and human studies.

The mechanism operates on two levels. At the cellular level, CJC-1295 activates the GHRH receptor on pituitary somatotrophs, initiating a Gs-coupled signaling (also known as signaling) cascade through adenylyl cyclase, cyclic AMP, and protein kinase A (PKA). This primes the cell for GH gene transcription and granule exocytosis. ⁽⁴⁾ Ipamorelin, acting at GHS-R1a, triggers a separate intracellular cascade through phospholipase C, inositol trisphosphate (IP3), and diacylglycerol (DAG), resulting in calcium mobilization (also referred to as mobilization) from intracellular stores that directly stimulates secretory granule fusion with the cell membrane. ^(2,3) When both cascades are active simultaneously, the somatotroph receives converging signals from two independent amplification pathways, producing a GH release event that is larger in amplitude and more tightly pulsatile than either pathway alone.

At the systemic level, ghrelin-receptor activation by Ipamorelin also suppresses somatostatin release from the hypothalamus. ^(3,4) Somatostatin is the primary inhibitory brake on GH secretion. By reducing somatostatin tone while CJC-1295 is pushing the accelerator through GHRH-receptor stimulation, the combination removes the physiological ceiling that would otherwise cap the GH pulse. The result is a higher peak amplitude and a cleaner pulse profile.

This dual-receptor synergy is why the CJC-1295 Ipamorelin pairing has become the default protocol in GH-axis research. It produces greater GH output than higher doses of either peptide alone, while maintaining the selectivity advantage that Ipamorelin provides over less selective ghrelin-receptor agonists like GHRP-6 and GHRP-2.

The research interest in CJC-1295 and Ipamorelin, both individually and in combination, spans the GH axis, body composition, sleep architecture, recovery, and metabolic parameters. The blend’s value lies in achieving these outcomes through synergistic dual-pathway stimulation rather than through higher doses of a single agent.

Growth Hormone and IGF-1 Amplification

The primary measurable outcome of CJC-1295 Ipamorelin administration is elevated circulating GH and downstream IGF-1. Human pharmacokinetic data for CJC-1295 (with DAC) showed GH increases of 2- to 10-fold and IGF-1 increases of 1.5- to 3-fold after a single injection. ⁽⁵⁾ Ipamorelin, in preclinical swine models, demonstrated GH-releasing potency comparable to GHRP-6 but without the cortisol and ACTH increases. ⁽²⁾ When the two are combined, research protocols consistently report GH pulse amplitudes that exceed either compound used individually at equivalent doses, a direct consequence of the dual-receptor synergy described above. ⁽³⁾

Body Composition

GH stimulates lipolysis, the breakdown and mobilization of stored fat for energy use, while IGF-1 drives protein synthesis in skeletal muscle through the PI3K/Akt/mTOR pathway. ^(4,6) The elevated GH and IGF-1 output from the CJC-1295 Ipamorelin pairing supports research into lean mass accrual and fat mass reduction in controlled experimental models. Ipamorelin’s selectivity is particularly relevant here: because it does not elevate cortisol (a catabolic hormone that promotes fat storage and muscle breakdown), the anabolic signal from GH and IGF-1 operates without a competing catabolic counterforce. ⁽²⁾ This clean hormonal profile is one reason the CJC-1295 Ipamorelin pairing has largely replaced older GHRH + GHRP-6 or GHRH + GHRP-2 combinations in body composition research, where cortisol confounding was a persistent methodological concern.

Sleep Quality

GHRH has a well-documented role in regulating slow-wave (deep) sleep architecture, independent of its effects on GH secretion. Exogenous GHRH administration in healthy subjects increased both the duration and intensity of slow-wave sleep in controlled studies. ⁽⁷⁾ Since the largest endogenous GH pulses occur during deep sleep, a peptide combination that both amplifies the GH pulse and supports the sleep stage in which that pulse naturally peaks represents a dual mechanism of interest for sleep-focused research protocols.

Recovery and Tissue Repair

IGF-1 is a key mediator of tissue repair processes, including collagen synthesis, osteoblast activity, satellite cell activation in skeletal muscle, and tendon remodeling (also spelled remodeling). ⁽⁶⁾ The amplified IGF-1 output from the CJC-1295 Ipamorelin combination has driven interest in this pairing for recovery-focused research models examining wound healing timelines, musculoskeletal repair, and connective tissue regeneration.

No regulatory body has established dosing guidelines for the CJC-1295 Ipamorelin combination. All dosage information in the research literature derives from individual-component studies, preclinical combination data, and community-reported protocols.

In the Teichman et al.  ⁽²⁰⁰⁶⁾ human trials of CJC-1295 (with DAC), subcutaneous doses of 30 to 60 micrograms per kilogram produced significant GH and IGF-1 elevation with the most favorable (also spelled favorable) tolerability profiles. ⁽⁵⁾ For Ipamorelin, Raun et al.  ⁽¹⁹⁹⁸⁾ reported GH release in swine at an ED50 of 2.3 nmol/kg, with GH-selectivity maintained even at doses exceeding 200-fold above this threshold. ⁽²⁾ These individual-component data points inform, but do not directly dictate, combination dosing.

The Healius CJC-1295 Ipamorelin Blend is supplied as a 10mg vial containing 5mg CJC-1295, no DAC, and 5mg Ipamorelin. Adding 2.0 mL of bacteriostatic water yields a final blend concentration of 5 mg/mL (2.5 mg/mL for each component). At this concentration, a 0.10 mL injection (10 units on a standard U-100 insulin syringe) delivers a total of 500 mcg, consisting of 250 mcg CJC-1295 without DAC and 250 mcg Ipamorelin. Researchers can adjust the reconstitution volume to achieve different per-unit concentrations according to their protocol requirements.

Both components have short half-lives (approximately 30 minutes for CJC-1295 no DAC; similar for Ipamorelin), which means the GH pulse from a single administration peak within 15 to 30 minutes and returns toward baseline within 2 to 3 hours. This pharmacokinetic profile supports pulsatile dosing strategies aligned with the body’s natural GH secretion rhythm rather than sustained continuous elevation. Because the largest endogenous GH pulses occur during deep slow-wave sleep, evening administration of the blend has become the standard timing approach in protocols designed to amplify the natural nocturnal GH surge. Protocols that include multiple daily administrations typically space doses at least 3 hours apart to allow baseline GH levels to reset between pulses, preserving the pulsatile pattern and reducing the theoretical risk of receptor desensitization (also referred to as desensitization).

For precise dose calculations based on your reconstitution volume and target per-injection dose, use the CJC-1295 Ipamorelin Dosage Calculator. Healius Bacteriostatic Water is available in matched volumes for reconstitution.

Neither CJC-1295 nor Ipamorelin has received FDA approval for therapeutic use, and long-term safety data in humans are lacking. The available safety information draws from individual-component trials and the broader GHRH/GHRP literature.

CJC-1295: In the Teichman et al.  ⁽²⁰⁰⁶⁾ ascending-dose trials (DAC form), the compound was reported as safe and relatively well tolerated at doses of 30 to 60 mcg/kg. No serious adverse events were attributed to the study drug. Reported effects included transient injection-site reactions (redness, swelling), facial flushing, headache, dizziness, and mild water retention. ⁽⁵⁾ ConjuChem Biotechnologies discontinued its Phase II program after a trial participant’s death, which the attending physician attributed to pre-existing asymptomatic coronary artery disease, unrelated to CJC-1295. ⁽⁸⁾

Ipamorelin: The defining safety characteristic of Ipamorelin is its selectivity. Raun et al.  ⁽¹⁹⁹⁸⁾ demonstrated that even at doses exceeding 200 times the GH-releasing ED50, Ipamorelin did not produce cortisol or ACTH elevations significantly different from baseline, a profile unmatched by GHRP-6 or GHRP-2 at equivalent GH-stimulating doses. ⁽²⁾ This selectivity reduces the risk of glucocorticoid-related side effects that complicate protocols using less selective ghrelin-receptor agonists.

For the combination, the expected side-effect profile reflects the individual components: transient injection-site discomfort, brief flushing, possible headache, and mild water retention, all consistent with an acute rise in circulating GH. The short half-lives of both peptides mean that any GH-mediated effects peak and resolve within hours rather than persisting. Researchers should note that both compounds are investigational and lack completed long-term safety evaluations, and all use must comply with applicable institutional and regulatory requirements.

Single-agent GHRH protocols using Sermorelin or Tesamorelin stimulate GH release via a single receptor pathway: the GHRH receptor. They do not engage the ghrelin receptor, do not suppress somatostatin, and do not produce the synergistic pulse amplification that a GHRH + GHRP combination generates.

Sermorelin, the unmodified GRF (1-29) fragment, has a half-life of under 10 minutes and produces a relatively modest GH pulse that clears rapidly. ⁽¹⁾ It held FDA approval as Geref but was voluntarily withdrawn for commercial reasons. Tesamorelin, a full-length 44-amino-acid GHRH analog with FDA approval as Egrifta SV for HIV-associated lipodystrophy, produces a larger and longer GH stimulus than sermorelin and has the strongest clinical data for visceral fat reduction of any peptide in this class. ⁽⁹⁾ Both are effective single-agent GHRH tools, but neither activates the ghrelin receptor.

The CJC-1295 Ipamorelin blend adds the ghrelin-receptor pathway on top of GHRH-receptor stimulation. This produces a dual-axis signal: the GHRH side (CJC-1295) primes somatotrophs to produce and release GH. In contrast, the GHRP side (Ipamorelin) amplifies the magnitude of each GH pulse and simultaneously suppresses somatostatin inhibition. ^(3,4) The net effect, demonstrated across preclinical and pharmacokinetic studies, is a significantly larger and more physiologically patterned GH pulse than any single-agent protocol achieves.

For researchers who need a single-agent GHRH, Healius stocks both Sermorelin and Tesamorelin. For researchers seeking maximal GH-axis stimulation with preserved hormonal selectivity, the CJC-1295 Ipamorelin Blend provides the dual-receptor combination in a single verified preparation.

1. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation, 1989;83(5):1533-1540. Established DPP-IV degradation of native GHRH and the rationale for amino acid substitutions in CJC-1295/Mod GRF 1-29.

2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin is the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552-561. Demonstrated ipamorelin’s GH-releasing potency comparable to GHRP-6 with selectivity unmatched by any other GHRP: no significant cortisol, prolactin, or ACTH elevation even at >200x ED50.

3. Bowers CY. GH releasing peptides: structure and kinetics. Journal of Pediatric Endocrinology & Metabolism, 1999;12(Suppl 3):723-728. Demonstrated that simultaneous GHRH + GHRP receptor stimulation produces a synergistic GH response significantly greater than the sum of individual stimuli.

4. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and humans. Endocrine Reviews, 1998;19(6):717-797. Review of GHRH-somatostatin-GH axis signaling, pulsatile secretion, feedback regulation, and dual-receptor convergence on somatotrophs.

5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhler SA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799-805. Demonstrated 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases in healthy human subjects.

6. Thomas MJ. The molecular basis of growth hormone action. Growth Hormone & IGF Research, 2001;11(Suppl A): S97-S103. Reviewed downstream GH effects, including lipolysis, protein synthesis, IGF-1 hepatic production, bone mineralization, and tissue repair.

7. Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology, 1992;56(4):566-573. Demonstrated GHRH-induced increases in slow-wave sleep duration and intensity.

8. ConjuChem Biotechnologies. CJC-1295 clinical program discontinuation. The attending physician attributed the participant’s death to pre-existing asymptomatic coronary artery disease with plaque rupture, unrelated to CJC-1295 treatment.

9. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357(23):2359-2370. Phase III trial of tesamorelin for HIV-associated lipodystrophy, forming the basis for FDA approval as Egrifta.

10. World Anti-Doping Agency. 2025 Prohibited List: International Standard. Section S2.2.4: Growth Hormone Releasing Factors. CJC-1295 and Ipamorelin are both explicitly named as prohibited at all times.

CJC-1295 Ipamorelin Blend is sold by Healius Peptides exclusively for in vitro research and laboratory use. It is not intended for human or veterinary therapeutic use, food, cosmetic, or household application. This product is not a drug, food supplement, or cosmetic product, and it may not be misbranded, misused, or mislabelled as such. By purchasing this product, the buyer acknowledges that it will be used solely for research purposes in accordance with all applicable local, state, national, and international laws and regulations. Healius Peptides assumes no liability for any misuse of this product.